Caligan Partners LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001727492
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2024 · 14 positions · Total reported value $394.88M · Top-10 concentration 94.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 25.0% · 2 new · 2 cut · 3 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q4 2024 13F filing, Caligan Partners LP disclosed 14 equity positions with a combined reported value of $394.88M. The filing implies a focused portfolio: its ten largest positions account for 94.3% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2024 were LQDA ($115.53M), VRNA ($66.73M), EXEL ($50.81M). By sector, the heaviest allocations are Health Care 72.7%, Other 27.3%. Versus the prior quarter, allocation shifted toward Other (+9.2pp) and away from Health Care (-9.2pp).
Versus the prior quarter, Caligan Partners LP opened 2 new positions, trimmed 2 and fully exited 3, a turnover rate of 25.0% of positions. The portfolio's overlap with the prior quarter was 62% of names.
The largest new positions opened in Q4 2024 were SAGE ($16.58M), MRUS ($10.72M), ABVX ($5.51M).
Of the 3 positions fully exited versus the prior quarter, the largest were NBP ($4.34M), OTLK ($1.70M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2024)
Insider Transactions (Form 4)
Latest Caligan Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-16 | Award | Liquidia Corp | 5,882 | — | SEC filing |
| 2026-05-19 | Buy | Liquidia Corp | 5,300 | $59.98 | SEC filing |
| 2026-05-19 | Sell | Liquidia Corp | 5,300 | $59.98 | SEC filing |
Fund Profile
Caligan Partners LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 25 US equity positions with a combined value of $1.63B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-113810 (status: Approved), registered 2018-08-10
- Regulatory AUM (Form ADV): $1.30B as of 2026-10-30
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 3 private funds, of which 3 hedge funds
- Website: caliganpartners.com
Portfolio Structure
- 25 positions · $1.63B reported value (Q3 2026)
- Top 10 holdings = 79.4% of reported value
- Largest position: RVMD (REVOLUTION MEDICINES INC) at 24.6%
- Average position size: $65.36M
Sector Tilt
- Health Care 98.2%
- (classified holdings cover 98% of value)
Quarterly Activity
- Q3 2026: 2 new, 12 added, 2 reduced, 3 exited
- 9 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
8.12M | $115.53M | 29.26% | Hold | |
| 2 |
|
1.44M | $66.73M | 16.90% | Hold | |
| 3 |
|
1.53M | $50.81M | 12.87% | Hold | |
| 4 |
|
2.69M | $29.72M | 7.53% | Add | |
| 5 |
|
1.44M | $23.62M | 5.98% | Hold | |
| 6 |
|
3.00M | $22.53M | 5.71% | Add | |
| 7 |
|
626.28K | $20.58M | 5.21% | Add | |
| 8 |
|
3.05M | $16.58M | 4.20% | New | |
| 9 |
|
1.77M | $13.84M | 3.51% | Add | |
| 10 |
|
1.01M | $12.45M | 3.15% | Add | |
| 11 |
|
255.00K | $10.72M | 2.71% | New | |
| 12 |
|
752.17K | $5.51M | 1.39% | New | |
| 13 |
|
7.43M | $5.20M | 1.32% | New | |
| 14 |
|
184.83K | $1.06M | 0.27% | Reduce | |
FAQ
What did Caligan Partners LP buy in 2024-Q4?
In its 2024-Q4 13F filing, Caligan Partners LP reported 14 equity positions worth $394.88M in aggregate; its largest disclosed positions were LQDA ($115.53M), VRNA ($66.73M), EXEL ($50.81M).
How large is Caligan Partners LP's portfolio?
Caligan Partners LP reported $394.88M of long equity holdings across 14 positions as of 2024-Q4. Top-10 holdings account for 94.3% of reported value.
What is Caligan Partners LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.